Technical Analysis for RNXT - RenovoRx, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Crossed Above 20 DMA | Bullish | 0.00% | |
NR7 | Range Contraction | 0.00% | |
Narrow Range Bar | Range Contraction | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
200 DMA Resistance | Bearish | 1.77% | |
Fell Below 20 DMA | Bearish | 1.77% | |
Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 1.77% | |
Wide Bands | Range Expansion | 1.77% | |
Gapped Up | Strength | 1.77% | |
Crossed Above 20 DMA | Bullish | -0.86% |
Alert | Time |
---|---|
Rose Above 20 DMA | about 10 hours ago |
Up 1% | about 10 hours ago |
Rose Above Previous Day's High | 3 days ago |
200 DMA Resistance | 3 days ago |
10 DMA Resistance | 3 days ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 08/15/2024
RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trial for the locally advanced pancreatic cancer. The company was founded in 2009 and is headquartered in Los Altos, California.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Clinical Medicine Solid Tumors Drugs Cancer Treatment Pancreatic Cancer Oncolytics Biotech Gastrointestinal Cancer Evofosfamide Gemcitabine
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Clinical Medicine Solid Tumors Drugs Cancer Treatment Pancreatic Cancer Oncolytics Biotech Gastrointestinal Cancer Evofosfamide Gemcitabine
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 2.39 |
52 Week Low | 0.5488 |
Average Volume | 43,338 |
200-Day Moving Average | 1.22 |
50-Day Moving Average | 1.23 |
20-Day Moving Average | 1.14 |
10-Day Moving Average | 1.20 |
Average True Range | 0.11 |
RSI (14) | 47.37 |
ADX | 18.47 |
+DI | 21.17 |
-DI | 18.70 |
Chandelier Exit (Long, 3 ATRs) | 1.07 |
Chandelier Exit (Short, 3 ATRs) | 1.34 |
Upper Bollinger Bands | 1.33 |
Lower Bollinger Band | 0.95 |
Percent B (%b) | 0.53 |
BandWidth | 34.05 |
MACD Line | -0.02 |
MACD Signal Line | -0.02 |
MACD Histogram | 0.002 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 1.22 | ||||
Resistance 3 (R3) | 1.22 | 1.19 | 1.21 | ||
Resistance 2 (R2) | 1.19 | 1.17 | 1.19 | 1.21 | |
Resistance 1 (R1) | 1.17 | 1.16 | 1.17 | 1.17 | 1.20 |
Pivot Point | 1.14 | 1.14 | 1.14 | 1.14 | 1.14 |
Support 1 (S1) | 1.12 | 1.12 | 1.13 | 1.13 | 1.10 |
Support 2 (S2) | 1.09 | 1.11 | 1.10 | 1.09 | |
Support 3 (S3) | 1.07 | 1.09 | 1.09 | ||
Support 4 (S4) | 1.08 |